



Factors associated with Acquired Anti IFN- γ autoantibody in Patients with Nontuberculous Mycobacterial Infection

Pakpoom Phoempoung¹, Nasikarn Ankasekwinai¹, Suporn Foongladda¹, Pinklow Umrod¹, Manop Pithukpakorn¹, Bhoon Suktitipat¹, Surakhameth Mahasirimongkol², Sasisopin Kiertiburanakul³, Yupin Suputtamongkol¹

¹Faculty of Medicine, Siriraj Hospital. ²Department of Medical Science, Ministry of Public Health. ³Faculty of Medicine, Ramathibodi Hospital. Bangkok, Thailand

2 Prannok Rd, Bangkoknoi, Bangkok, Thailand, 10700

Email: benefat@hotmail.com Tel: 6682-419-7783

Background	Result	Table1: Baseline characteristics	Table2: Nontuberculous mycobacterial disease	Conclusion																																																																																																																
<ul style="list-style-type: none"> Disseminated nontuberculous mycobacterial (NTM) diseases in non-HIV infected patients is now well recognized in association with an acquired autoantibody to Interferon-gamma (anti-IFN γ autoantibody)¹. Risk factors of this syndrome are unknown. 	<ul style="list-style-type: none"> 70 cases and 72 controls. Baseline characteristics are shown in Table 1. <i>Mycobacterial abscessus</i> was the most common NTM pathogen found in both groups. Disseminated NTM disease was significantly more common in cases (92.9%) than in controls (13.9%, $p < 0.001$). Details of NTM species and site of isolation are shown in Table 2. Among cases, 44 patients (62.9%) developed reactive skin lesions associated with active NTM diseases; sweet syndrome (37.1%), acute generalized exanthematous pustulosis (20%) and erythema nodosum (14.3%). Reactive arthritis was also detected in 6 patients among cases (8.6%). Anemia, leukocytosis, eosinophilia and thrombocytosis were more common among cases than among controls. ESR and CRP were significantly higher in cases. Higher globulin and lower albumin levels in cases were observed. Independent factors associated with anti-IFN γ autoantibody were shown in Table 3. 	<table border="1"> <thead> <tr> <th>Variable</th> <th>Case</th> <th>Control</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Male, n (%)</td> <td>40 (57.1)</td> <td>39 (54.2)</td> <td>0.721</td> </tr> <tr> <td>Mean (SD) age, yrs</td> <td>50 (11)</td> <td>58 (19)</td> <td>0.002</td> </tr> <tr> <td>Birthplace, n (%)</td> <td></td> <td></td> <td>< 0.001</td> </tr> <tr> <td>- Central</td> <td>21 (30)</td> <td>53 (73.6)</td> <td></td> </tr> <tr> <td>- Northeast</td> <td>18 (25.7)</td> <td>3 (4.2)</td> <td></td> </tr> <tr> <td>- North</td> <td>16 (22.9)</td> <td>1 (1.4)</td> <td></td> </tr> <tr> <td>- West</td> <td>10 (14.3)</td> <td>6 (8.3)</td> <td></td> </tr> <tr> <td>- Other</td> <td>5 (7.1)</td> <td>9 (12.5)</td> <td></td> </tr> <tr> <td>Comorbidities, n (%)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- Yes</td> <td>4 (5.7)</td> <td>25 (34.7)</td> <td>< 0.001</td> </tr> <tr> <td>Previous OIs, n (%)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- Yes</td> <td>33 (47.1)</td> <td>11 (15.3)</td> <td>< 0.001</td> </tr> <tr> <td>HLA studies</td> <td></td> <td></td> <td></td> </tr> <tr> <td>no tested, no+ve (%ve)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- DRB1*15/16:02</td> <td>61,49 (80.3)</td> <td>54,11 (20.3)</td> <td>< 0.001</td> </tr> <tr> <td>- DQB1*05:01/02</td> <td>61,59 (96.7)</td> <td>53,17 (32.1)</td> <td>< 0.001</td> </tr> </tbody> </table>	Variable	Case	Control	p-value	Male, n (%)	40 (57.1)	39 (54.2)	0.721	Mean (SD) age, yrs	50 (11)	58 (19)	0.002	Birthplace, n (%)			< 0.001	- Central	21 (30)	53 (73.6)		- Northeast	18 (25.7)	3 (4.2)		- North	16 (22.9)	1 (1.4)		- West	10 (14.3)	6 (8.3)		- Other	5 (7.1)	9 (12.5)		Comorbidities, n (%)				- Yes	4 (5.7)	25 (34.7)	< 0.001	Previous OIs, n (%)				- Yes	33 (47.1)	11 (15.3)	< 0.001	HLA studies				no tested, no+ve (%ve)				- DRB1*15/16:02	61,49 (80.3)	54,11 (20.3)	< 0.001	- DQB1*05:01/02	61,59 (96.7)	53,17 (32.1)	< 0.001	<table border="1"> <thead> <tr> <th>Variable, n (%)</th> <th>Case</th> <th>Control</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Type of NTM</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- Rapid grower</td> <td>57 (81.4)</td> <td>44 (61.1)</td> <td>0.008</td> </tr> <tr> <td>Species of NTM</td> <td></td> <td></td> <td></td> </tr> <tr> <td>- <i>M. abscessus</i></td> <td>51 (72.9)</td> <td>30 (41.7)</td> <td>< 0.001</td> </tr> <tr> <td>- MAC</td> <td>8 (11.4)</td> <td>15 (20.8)</td> <td></td> </tr> <tr> <td>- <i>M. fortuitum</i></td> <td>7 (10)</td> <td>12 (16.7)</td> <td></td> </tr> <tr> <td>- <i>M. kansasii</i></td> <td>1 (1.4)</td> <td>6 (8.3)</td> <td></td> </tr> <tr> <td>- <i>M. simiae</i></td> <td>1 (1.4)</td> <td>2 (2.8)</td> <td></td> </tr> <tr> <td>- <i>M. haemophilum</i></td> <td>1 (1.4)</td> <td>1 (1.4)</td> <td></td> </tr> <tr> <td>- Others</td> <td>0 (0)</td> <td>3 (4.2)</td> <td></td> </tr> </tbody> </table>	Variable, n (%)	Case	Control	p-value	Type of NTM				- Rapid grower	57 (81.4)	44 (61.1)	0.008	Species of NTM				- <i>M. abscessus</i>	51 (72.9)	30 (41.7)	< 0.001	- MAC	8 (11.4)	15 (20.8)		- <i>M. fortuitum</i>	7 (10)	12 (16.7)		- <i>M. kansasii</i>	1 (1.4)	6 (8.3)		- <i>M. simiae</i>	1 (1.4)	2 (2.8)		- <i>M. haemophilum</i>	1 (1.4)	1 (1.4)		- Others	0 (0)	3 (4.2)		<ul style="list-style-type: none"> Patients with NTM disease associated with anti-IFN γ autoantibody were almost always previously healthy and non-HIV infected. Nearly all of them presented with disseminated NTM diseases, in association with reactive skin lesions. Factors associated with this syndrome were lack of comorbidities, birthplace in non-central region of Thailand, previous OIs and specific HLA
Variable	Case	Control	p-value																																																																																																																	
Male, n (%)	40 (57.1)	39 (54.2)	0.721																																																																																																																	
Mean (SD) age, yrs	50 (11)	58 (19)	0.002																																																																																																																	
Birthplace, n (%)			< 0.001																																																																																																																	
- Central	21 (30)	53 (73.6)																																																																																																																		
- Northeast	18 (25.7)	3 (4.2)																																																																																																																		
- North	16 (22.9)	1 (1.4)																																																																																																																		
- West	10 (14.3)	6 (8.3)																																																																																																																		
- Other	5 (7.1)	9 (12.5)																																																																																																																		
Comorbidities, n (%)																																																																																																																				
- Yes	4 (5.7)	25 (34.7)	< 0.001																																																																																																																	
Previous OIs, n (%)																																																																																																																				
- Yes	33 (47.1)	11 (15.3)	< 0.001																																																																																																																	
HLA studies																																																																																																																				
no tested, no+ve (%ve)																																																																																																																				
- DRB1*15/16:02	61,49 (80.3)	54,11 (20.3)	< 0.001																																																																																																																	
- DQB1*05:01/02	61,59 (96.7)	53,17 (32.1)	< 0.001																																																																																																																	
Variable, n (%)	Case	Control	p-value																																																																																																																	
Type of NTM																																																																																																																				
- Rapid grower	57 (81.4)	44 (61.1)	0.008																																																																																																																	
Species of NTM																																																																																																																				
- <i>M. abscessus</i>	51 (72.9)	30 (41.7)	< 0.001																																																																																																																	
- MAC	8 (11.4)	15 (20.8)																																																																																																																		
- <i>M. fortuitum</i>	7 (10)	12 (16.7)																																																																																																																		
- <i>M. kansasii</i>	1 (1.4)	6 (8.3)																																																																																																																		
- <i>M. simiae</i>	1 (1.4)	2 (2.8)																																																																																																																		
- <i>M. haemophilum</i>	1 (1.4)	1 (1.4)																																																																																																																		
- Others	0 (0)	3 (4.2)																																																																																																																		
<p>Method</p> <ul style="list-style-type: none"> Unmatched case-control study among patients with NTM disease. Anti-IFN γ autoantibody was assayed by enzyme-linked immunosorbent assay. Cases were patients with NTM disease and detectable anti-IFN γ autoantibody. Controls were randomly selected from those with NTM disease but undetectable anti-IFN γ autoantibody. Data collection included demographic data, clinical presentations, laboratory results and suspected risk factors such as HLA analysis. Univariate and multivariate analyses were performed to identify factors associated with this syndrome. 			<p>Table 3: Associated factors</p> <table border="1"> <thead> <tr> <th>Factors</th> <th>Crude OR</th> <th>Adjusted OR</th> <th>95%CI</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Age</td> <td>0.97</td> <td>0.97</td> <td>0.94-1.01</td> <td>0.164</td> </tr> <tr> <td>Comorbidities</td> <td>0.11</td> <td>0.11</td> <td>0.03-0.48</td> <td>0.003</td> </tr> <tr> <td>Birthplace in central region</td> <td>0.15</td> <td>0.24</td> <td>0.08-0.73</td> <td>0.012</td> </tr> <tr> <td>Previous OIs</td> <td>4.95</td> <td>5.94</td> <td>1.50-23.59</td> <td>0.011</td> </tr> <tr> <td>HLA DRB1*15/16:02</td> <td>29.5</td> <td>21.69</td> <td>5.06-92.92</td> <td>< 0.001</td> </tr> <tr> <td>DQB1*05:01/02</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	Factors	Crude OR	Adjusted OR	95%CI	p-value	Age	0.97	0.97	0.94-1.01	0.164	Comorbidities	0.11	0.11	0.03-0.48	0.003	Birthplace in central region	0.15	0.24	0.08-0.73	0.012	Previous OIs	4.95	5.94	1.50-23.59	0.011	HLA DRB1*15/16:02	29.5	21.69	5.06-92.92	< 0.001	DQB1*05:01/02					<p>Acknowledgement</p> <p>Funding by National Science and Technology Development Agency (NSTDA), Thailand.</p> <p>Reference</p> <ol style="list-style-type: none"> Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. <i>N Engl J Med.</i> 2012;367(8):725-34. Pithukpakorn M, Roothumnong E, Angkasekwinai N, Suktitipat B, Assawamakin A, Luangwedchakarn V, et al. HLA-DRB1 and HLA-DQB1 are Associated with Adult-Onset Immunodeficiency with Acquired Anti-Interferon-Gamma Autoantibodies. <i>PLoS One.</i> 2015;10(5):e0128481. 																																																																													
Factors	Crude OR	Adjusted OR	95%CI	p-value																																																																																																																
Age	0.97	0.97	0.94-1.01	0.164																																																																																																																
Comorbidities	0.11	0.11	0.03-0.48	0.003																																																																																																																
Birthplace in central region	0.15	0.24	0.08-0.73	0.012																																																																																																																
Previous OIs	4.95	5.94	1.50-23.59	0.011																																																																																																																
HLA DRB1*15/16:02	29.5	21.69	5.06-92.92	< 0.001																																																																																																																
DQB1*05:01/02																																																																																																																				